• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在MIPLATE随机试验中,接受Mirasol血小板与标准血小板后产生HLA抗体的风险。

Risk of HLA antibody generation after receipt of Mirasol versus standard platelets in the MIPLATE randomized trial.

作者信息

Kaidarova Zhanna, Di Germanio Clara, Custer Brian, Norris Philip J

机构信息

Vitalant Research Institute, San Francisco, California, USA.

Department of Laboratory Medicine, University of California, San Francisco, California, USA.

出版信息

Transfusion. 2023 Apr;63(4):791-797. doi: 10.1111/trf.17286. Epub 2023 Feb 25.

DOI:10.1111/trf.17286
PMID:36840440
Abstract

BACKGROUND

Human leukocyte antigen (HLA) alloimmunization can occur after platelet transfusion. These antibodies can complicate future platelet transfusions or organ transplantation. Animal data suggest that Mirasol pathogen reduction treatment (PRT) can prevent alloimmunization after transfusion.

STUDY DESIGN AND METHODS

The MIPLATE trial enrolled 330 of a planned 660 participants with hematological malignancies at risk for grade 2 or greater bleeding. The study was halted early for futility after a planned interim analysis. Participants were randomized to receive PRT versus standard control platelets. Serum samples were collected from participants at baseline (pretransfusion), weekly for the first 4 weeks, then at days 42 and 56. HLA antibody levels were determined using a commercial multianalyte bead-based assay. HLA antibody levels were analyzed using low, medium, and high cutoffs based on prior studies.

RESULTS

The rate of alloimmunization was low in both arms of the study, particularly at the high HLA antibody cutoff (total of 6 of 277 subjects at risk, or 2.2%). The risk of alloimmunization did not differ between study arms, nor did the risk of immune refractoriness to platelet transfusion.

CONCLUSIONS

The data do not support the conclusion that Mirasol exerted a protective effect against alloimmunization after platelet transfusion in the MIPLATE trial.

摘要

背景

血小板输注后可发生人类白细胞抗原(HLA)同种免疫。这些抗体可使未来的血小板输注或器官移植变得复杂。动物数据表明,Mirasol病原体灭活处理(PRT)可预防输血后的同种免疫。

研究设计与方法

MIPLATE试验纳入了计划招募的660名有2级或更高级别出血风险的血液系统恶性肿瘤患者中的330名。在计划的中期分析后,该研究因无效而提前终止。参与者被随机分配接受PRT处理的血小板与标准对照血小板。在基线(输血前)、前4周每周、然后在第42天和第56天从参与者收集血清样本。使用基于商业多分析物微珠的检测方法测定HLA抗体水平。根据先前的研究,使用低、中和高临界值分析HLA抗体水平。

结果

研究的两个组中同种免疫的发生率都很低,特别是在高HLA抗体临界值时(277名有风险的受试者中共有6名,即2.2%)。研究组之间同种免疫的风险没有差异,对血小板输注产生免疫不应性的风险也没有差异。

结论

在MIPLATE试验中,数据不支持Mirasol对血小板输注后同种免疫有保护作用这一结论。

相似文献

1
Risk of HLA antibody generation after receipt of Mirasol versus standard platelets in the MIPLATE randomized trial.在MIPLATE随机试验中,接受Mirasol血小板与标准血小板后产生HLA抗体的风险。
Transfusion. 2023 Apr;63(4):791-797. doi: 10.1111/trf.17286. Epub 2023 Feb 25.
2
Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: results from a randomized trial.基于紫外线的血小板输注后病原体灭活及同种免疫:一项随机试验的结果
Transfusion. 2018 May;58(5):1210-1217. doi: 10.1111/trf.14534. Epub 2018 Feb 22.
3
The role of pathogen-reduced platelet transfusions on HLA alloimmunization in hemato-oncological patients.去病原体血小板输注在血液肿瘤患者 HLA 同种免疫中的作用。
Transfusion. 2019 Feb;59(2):470-481. doi: 10.1111/trf.15056. Epub 2018 Nov 30.
4
Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.HLA 同种免疫导致的血小板输注无效:机制和管理方面的不断变化的模式。
Blood Rev. 2023 Nov;62:101135. doi: 10.1016/j.blre.2023.101135. Epub 2023 Oct 2.
5
Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.人类白细胞抗原同种免疫与同种免疫性血小板输注无效
Transfus Med Rev. 2020 Oct;34(4):250-257. doi: 10.1016/j.tmrv.2020.09.010. Epub 2020 Oct 7.
6
Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.人类白细胞抗原 I 类抗体与肝移植患者血小板输注反应。
J Surg Res. 2020 Nov;255:99-105. doi: 10.1016/j.jss.2020.05.029. Epub 2020 Jun 16.
7
C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.在“减少血小板同种免疫试验”研究参与者中,C1q结合抗HLA抗体不能预测血小板输注失败。
Transfusion. 2016 Jun;56(6):1442-50. doi: 10.1111/trf.13598. Epub 2016 Apr 15.
8
Results of clinical effectiveness of conventional versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MiPLATE) trial.传统治疗与Mirasol处理的单采血小板治疗低增生性血小板减少症患者的临床疗效结果(MiPLATE)试验
Transfusion. 2024 Mar;64(3):457-465. doi: 10.1111/trf.17720. Epub 2024 Feb 5.
9
Pathogen-reduced platelets for the prevention of bleeding.用于预防出血的去病原体血小板。
Cochrane Database Syst Rev. 2013 Mar 28(3):CD009072. doi: 10.1002/14651858.CD009072.pub2.
10
In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice.胎内暴露于同种异体抗原可使小鼠对血小板输注产生同种免疫。
Transfusion. 2021 Mar;61(3):687-691. doi: 10.1111/trf.16224. Epub 2020 Dec 18.

引用本文的文献

1
Transfusion Support in Hematopoietic Stem Cell Transplantation: A Contemporary Narrative Review.造血干细胞移植中的输血支持:当代叙述性综述
Clin Hematol Int. 2024 Mar 25;6(1):128-140. doi: 10.46989/001c.94135. eCollection 2024.